Scientists at The Wellcome Sanger Institute have determined that the risk of suffering from a range of monogenic neurodevelopmental genetic disorders can be affected by common genetic variations.
At AAIC 2018, we had the pleasure of speaking with Catherine Kaczorowski about the innovative work she is doing to accelerate drug discovery in Alzheimer’s disease.
Researchers have revealed that RNA-binding proteins accumulate in the brains of people with non-heritable amyotrophic lateral sclerosis and frontotemporal dementia.
Researchers have developed a personalized neurological footprint, which uses a link between brain physiology, genetic profile and response to therapeutics, to predict the effectiveness of aiming treatment at various targets within individual patients.
Scientists have demonstrated how variations in a gene linked to anxiety and depression could affect a patient’s response to treatment.
In an international collaboration, researchers have determined that psychiatric disorders may have important molecular similarities that are not reflected in current diagnostic categories.
Scientists have identified novel genes associated with a specific form of schizophrenia, which could potentially aid diagnosis and development of treatments.
A novel study reveals that the placenta could play an imperative role in schizophrenia and possibly other neurodevelopmental disorders.
Researchers have uncovered three new genes that are linked to the possibility of developing Alzheimer’s disease; potentially unlocking new treatment possibilities for patients.
A preliminary study has revealed that an investigational drug may help increase protein levels in babies with spinal muscular atrophy.